Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinsonโs Disease and Mild Cognitive Impairment/early Alzheimerโs disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
์ข
๋ชฉ ์ฝ๋ JUNS
ํ์ฌ ์ด๋ฆJupiter Neurosciences Inc
์์ฅ์ผDec 03, 2024
CEORosen (Christer)
์ง์ ์4
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 03
์ฃผ์1001 North US HWY 1, Suite 504
๋์PALM BEACH GARDENS
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ33477
์ ํ15614066154
์น์ฌ์ดํธhttps://jupiterneurosciences.com/
์ข
๋ชฉ ์ฝ๋ JUNS
์์ฅ์ผDec 03, 2024
CEORosen (Christer)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์